Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30868512 | 1.00 | ALDH1A1 (0.68) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| SCHEMBL3991783 | 0.86 | MCL1 (0.65) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| Sulfosalicylic SCHEMBL29157636 | 0.85 | ALDH1A1 (0.86) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| SCHEMBL1042597 | 0.85 | LMNA (0.61) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| SCHEMBL1577295 | 0.85 | LMNA (0.51) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| SCHEMBL8962352 | 0.84 | LMNA (0.70) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| Sulfosalicylic SCHEMBL28150168 | 0.83 | ALDH1A1 (0.89) | ALDH1A1HSD17B10KDM4EHPGDCSNK2A1 | |
| SCHEMBL3527141 | 0.82 | ALDH1A1 (0.70) | ALDH1A1HSD17B10KDM4EHPGDCSNK2A1 | |
| Sulfosalicylic SCHEMBL6717073 | 0.82 | ALDH1A1 (0.96) | ALDH1A1HSD17B10KDM4EHPGDCSNK2A1 | |
| Sulfosalicylic SCHEMBL29364125 | 0.82 | ALDH1A1 (0.96) | ALDH1A1HSD17B10KDM4EHPGDCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-11072634-B2 | Inhibitors of transglutaminases | ZEDIRA GMBH (DE) | 2021-07-27 | — | — | US | disclosed |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| WO-2018122419-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2018-07-05 | — | — | WO | disclosed |
| EP-3342779-A1 | INHIBITORS OF TRANSGLUTAMINASES | Zedira GmbH (DE) | 2018-07-04 | — | — | EP | disclosed |
| CN-1867554-B | Piperazine with ortho-substituted phenyl and its use as GLYT1 inhibitors | HOFFMANN LA ROCHE | 2011-07-06 | — | — | CN | disclosed |
| US-7605163-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-10-20 | — | — | US | disclosed |
| WO-2008098978-A2 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | JOLIDON SYNESE | 2008-05-22 | — | — | US | disclosed |
| US-7319099-B2 | Such as 1-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl benzoyl)-piperazin-1-yl]-phenyl}-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| WO-1992009284-A1 | 2,6-METHANO-2H-1-BENZOXOCINCARBOXAMIDES AS 5-HT3-ANTAGONISTS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1992-06-11 | — | — | WO | disclosed |
| WO-1991004738-A1 | DIBENZOFURANCARBOXAMIDES | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-04-18 | — | — | WO | disclosed |
| US-4959485-A | 5-HT3 ANTAGONISTS | RORER PHARMACEUTICAL CORPORATION (US) | 1990-09-25 | — | — | US | disclosed |
| US-4939132-A | Novel 5-alkylsulfonylsalicylanilides and microbiocidal compositions for controlling the growth of microorganisms | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1990-07-03 | — | — | US | disclosed |
| US-4935511-A | Nervous system, gastrointestinal disorders | RORER PHARMACEUTICAL CORPORATION (US) | 1990-06-19 | — | — | US | disclosed |
| WO-1989010364-A1 | DIBENZOFURANCARBOXAMIDES | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-11-02 | — | — | WO | disclosed |
| EP-0339950-A2 | Dibenzofurancarboxamides, their use as pharmaceutical agents, a composition containing the same, and a process for the preparation thereof | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| US-4863921-A | Dibenzofurancarboxamides and their pharmaceutical compositions and methods | RORER PHARMACEUTICAL CORPORATION (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0198366-A1 | Novel 5-alkylsulfonylsalicylanlides and microbiocidal compositions for controlling the growth of microorganisms | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1986-10-22 | — | — | EP | disclosed |
| US-4006239-A | Benzoic acid amides for mycobacterium infections | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | SLC1A2, SLC18A2, SLC6A7 | ALDH1A1 1436/4885HSD17B10 2913/4885KDM4E 2701/4885 |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | ALDH1A1 1469/4885HSD17B10 1144/4885KDM4E 911/4885 |
| US-11072634-B2 | Inhibitors of transglutaminases | TGM2, TGM3, TGM1 | ALDH1A1 1469/4885HSD17B10 1144/4885KDM4E 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.